RIA Advisory Group LLC Acquires Shares of 73,257 Kodiak Sciences Inc. (NASDAQ:KOD)

RIA Advisory Group LLC bought a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 73,257 shares of the company’s stock, valued at approximately $191,000.

Other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new stake in shares of Kodiak Sciences during the third quarter worth $751,000. SG Americas Securities LLC bought a new position in shares of Kodiak Sciences during the 3rd quarter worth approximately $33,000. Sanctuary Advisors LLC bought a new position in shares of Kodiak Sciences in the second quarter valued at about $36,000. Squarepoint Ops LLC bought a new position in Kodiak Sciences in the 2nd quarter valued at about $127,000. Finally, Marshall Wace LLP increased its stake in shares of Kodiak Sciences by 41.6% during the second quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock worth $391,000 after purchasing an additional 48,930 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $5.53 on Friday. The firm has a 50 day moving average price of $3.36 and a two-hundred day moving average price of $3.05. Kodiak Sciences Inc. has a 52-week low of $1.89 and a 52-week high of $7.77.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01. Equities analysts expect that Kodiak Sciences Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on KOD shares. Barclays boosted their price objective on shares of Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Friday. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Friday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.20.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.